Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Voorwerk L1, Slagter M1,2,3, Horlings HM4, Sikorska K5, van de Vijver KK4,6, de Maaker M7, Nederlof I7, Kluin RJC8, Warren S9, Ong S9, Wiersma TG10, Russell NS10, Lalezari F11, Schouten PC7, Bakker NAM3,12, Ketelaars SLC1, Peters D13, Lange CAH11, van Werkhoven E5, van Tinteren H5, Mandjes IAM5, Kemper I14, Onderwater S14, Chalabi M1,15, Wilgenhof S14, Haanen JBAG1,14, Salgado R16,17, de Visser KE3,12, Sonke GS14, Wessels LFA2,3, Linn SC7,14, Schumacher TN1,3, Blank CU1,14, Kok M18,19. 1 Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 2 Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 3 Oncode Institute, Utrecht, the Netherlands. 4 Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 5 Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 6 Department of Pathology, Ghent University Hospital, Ghent, Belgium. 7 Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 8 Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 9 NanoString Technologies, Inc., Seattle, WA, USA. 10 Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 11 Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 12 Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 13 Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 14 Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 15 Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 16 Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium. 17 Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia. 18 Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl. 19 Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.